Antibodies | Immune-Related Adverse Events and Survival Outcomes in Cervical Cancer Patients Treated with Cemiplimab

This study provides real-world evidence on the safety and efficacy prediction of immunotherapy for cervical cancer, suggesting that the occurrence of irAEs may serve as a potential biomarker for PFS, offering guidance for optimizing clinical monitoring strategies.

 

Literature Overview

The article 'Immune-Related Adverse Events of Cemiplimab Therapy in Advanced Cervical Cancer—Data from the Polish–Czech Cervical Cancer Immunotherapy Group (PCCIG-01) with a Review of the Literature', published in the journal 'Antibodies', systematically investigates the incidence, severity, and association with treatment outcomes of immune-related adverse events (irAEs) in patients with advanced cervical cancer receiving cemiplimab in real-world clinical practice. Based on a multicenter, prospective–retrospective cohort design, this study fills a data gap in Central and Eastern Europe.

Background Knowledge

Cervical cancer ranks fourth in global female malignancies, with a heavier burden in Central and Eastern Europe due to lower HPV vaccination and screening coverage. For patients with recurrent, persistent, or metastatic cervical cancer, the prognosis is extremely poor, with a 5-year survival rate of only 17%. Although platinum-based chemotherapy with or without bevacizumab is the standard first-line treatment, efficacy remains limited. In recent years, immune checkpoint inhibitors (ICIs), particularly PD-1/PD-L1 pathway-targeting agents such as cemiplimab, have become important options for second-line or later therapy. However, their clinical use is associated with the risk of immune-related adverse events (irAEs), and the relationship between irAE occurrence and treatment efficacy is not yet fully understood. Currently, data on the long-term safety, irAE profiles, and their association with survival outcomes of PD-1 inhibitors in real-world settings, especially in specific regional populations, remain scarce. This study aims to systematically evaluate the irAE characteristics of cemiplimab therapy and explore their associations with PFS and OS through a multicenter real-world cohort from Poland and the Czech Republic, providing evidence for clinical decision-making and patient management.

 

 

Research Methods and Experiments

The study employed a multicenter, prospective–retrospective cohort design (PCCIG-01), enrolling 101 patients with persistent, recurrent, or metastatic cervical cancer treated with cemiplimab across 13 referral centers. Data collection included baseline characteristics, treatment details, adverse events (AEs), and survival outcomes. All AEs were graded according to CTCAE v5.0 and adjudicated for immune-related causality by investigators at each center. The primary endpoints were the incidence and severity of irAEs, while secondary endpoints included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and disease control rate (DCR). Survival analyses were performed using Kaplan–Meier methods and Cox proportional hazards models. Subgroup analyses focused on the impact of thyroid irAEs, with comparisons made to the pivotal phase III EMPOWER-Cervical 1 trial and other real-world studies.

Key Conclusions and Perspectives

• The irAE incidence was 33.7% (34/101), with most being grade 1–2, indicating that cemiplimab has a manageable safety profile in real-world settings. This suggests that clinical monitoring should focus on mild-to-moderate toxicities to avoid unnecessary treatment interruptions.
• Endocrine toxicity (mainly thyroid dysfunction) was the most common type of irAE (58.5%), followed by hepatic and gastrointestinal toxicities. This highlights the necessity of routine thyroid function monitoring as part of standard management when using PD-1 inhibitors.
• Patients experiencing irAEs had significantly longer median PFS (10.9 months vs 3.9 months, p=0.03). Multivariable analysis showed that irAEs were independently associated with a 54% reduction in the risk of disease progression or death (HR 0.46). This strongly supports irAEs as a potential predictive biomarker for PFS, offering significant value for developing efficacy prediction models in drug development.
• Although OS was numerically longer in patients with irAEs (not reached vs 15.3 months), the difference did not reach statistical significance (p=0.11). This may be due to sample size, short follow-up duration, and confounding from subsequent therapies, suggesting that OS is more challenging as an endpoint in real-world studies and requires larger samples for validation.
• Subgroup analysis showed that thyroid irAEs were associated with longer PFS and significantly longer adjusted OS, further supporting that specific irAEs may reflect a stronger antitumor immune response, providing clues for modeling immune activation states in disease simulations.

Research Significance and Prospects

This study provides important real-world evidence for immunotherapy in cervical cancer, confirming that cemiplimab has manageable safety and that irAE occurrence is associated with improved PFS. This suggests clinicians should balance treatment continuity with toxicity management, avoiding premature discontinuation due to mild toxicities. Moreover, irAEs, particularly thyroid dysfunction, may serve as practical clinical indicators for predicting treatment efficacy, helping to identify patient subgroups more likely to benefit.

From a research perspective, these findings emphasize the need to consider the relationship between safety and efficacy in drug development. Future studies should explore the biological mechanisms underlying irAE development, such as the expansion of specific T-cell clones or the production of autoantibodies, to identify more precise predictive biomarkers. Additionally, this study cohort provides a valuable resource for validating novel biomarkers, such as immune signatures in blood or tissue.

 

 

Conclusion

This study establishes the safety profile of cemiplimab in the real-world treatment of advanced cervical cancer and reveals a significant association between immune-related adverse events (irAEs) and longer progression-free survival (PFS). These findings not only reinforce the clinical value of irAEs as potential efficacy predictors but also provide direct evidence for optimizing patient management strategies. For laboratory research, this cohort offers an ideal model to investigate the immunological mechanisms underlying response to PD-1 inhibitors. From a translational medicine perspective, this study serves as a cornerstone linking fundamental immunological discoveries with clinical practice, suggesting that future individualized monitoring protocols based on irAE risk stratification could be developed to improve the care of cervical cancer patients and advance precision immunotherapy.

 

Radosław Łupkowski, Karolina Górniak, Maja Lisik-Habib, Paweł Blecharz, and Renata Pacholczak-Madej. Immune-Related Adverse Events of Cemiplimab Therapy in Advanced Cervical Cancer—Data from the Polish–Czech Cervical Cancer Immunotherapy Group (PCCIG-01) with a Review of the Literature. Antibodies.